430 Stock Overview
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Terns Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.04 |
| 52 Week High | US$7.70 |
| 52 Week Low | US$1.38 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 39.31% |
| 1 Year Change | -48.21% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 430 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.9% | 1.2% |
| 1Y | -48.2% | -28.2% | 2.0% |
Return vs Industry: 430 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 430 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 430 volatility | |
|---|---|
| 430 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 430's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 430's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 41 | Senthil Sundaram | www.ternspharma.com |
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity.
Terns Pharmaceuticals, Inc. Fundamentals Summary
| 430 fundamental statistics | |
|---|---|
| Market cap | €180.27m |
| Earnings (TTM) | -€56.90m |
| Revenue (TTM) | €968.20k |
186.2x
P/S Ratio-3.2x
P/E RatioIs 430 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 430 income statement (TTM) | |
|---|---|
| Revenue | US$1.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.00m |
| Other Expenses | US$59.77m |
| Earnings | -US$58.77m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.56 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,877.10% |
| Debt/Equity Ratio | 0% |
How did 430 perform over the long term?
See historical performance and comparison